Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
An update from Benitec Biopharma (BNTC) is now available.
Benitec Biopharma Inc. has released promising interim results from its BB-301 Phase 1b/2a study, showcasing the effects at the 180-day mark for the first subject treated with a low dose of their investigational drug, BB-301. This announcement could be a significant milestone for investors and those keeping an eye on the biopharmaceutical sector’s innovative therapies.
See more data about BNTC stock on TipRanks’ Stock Analysis page.
